Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncobiologics ONSI.W

Healthcare Biotechnology

Recent & Breaking News (NDAQ:ONSI.W)

Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

GlobeNewswire August 13, 2021

Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference

GlobeNewswire August 11, 2021

Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD

GlobeNewswire August 3, 2021

Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer

GlobeNewswire July 7, 2021

Outlook Therapeutics Announces Inclusion in the Russell 2000® Index

GlobeNewswire June 14, 2021

Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

GlobeNewswire June 8, 2021

Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010

GlobeNewswire May 27, 2021

Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update

GlobeNewswire May 14, 2021

Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021

GlobeNewswire May 12, 2021

Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire March 31, 2021

Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 4, 2021

Outlook Therapeutics to Participate in Cantor Fitzgerald's Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021

GlobeNewswire February 17, 2021

Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update

GlobeNewswire February 16, 2021

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire February 11, 2021

Outlook Therapeutics' Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg) Through Planned BLA Submission

GlobeNewswire February 4, 2021

Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal

GlobeNewswire February 2, 2021

Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock

GlobeNewswire January 28, 2021

Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics' ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire January 12, 2021

Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

GlobeNewswire January 5, 2021

Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update

GlobeNewswire December 23, 2020